Press releaseBusiness Wire
Niagen Bioscience
NAGE · NASDAQ
$2.51+$0.01 (+0.40%)TodayMarket closed ·
Prev close $2.50
Latest news
- Press releaseBusiness Wire
Niagen Bioscience to Report Third Quarter 2026 Financial Results on Wednesday, November 4, 2026
- Press releaseBusiness Wire
Andrew Shao, Ph.D., Senior Vice President of Global Regulatory and Scientific Affairs at Niagen Bioscience, Honored with the 2026 Annette Dickinson Trailblazer Award by Radicle Science and Council for Responsible Nutrition (CRN)
- Press releaseBusiness Wire
Niagen Bioscience to Present at LD Micro 20th Annual Main Event
- Press releaseBusiness Wire
Niagen Bioscience Puts 25 Years of NAD+ Science Behind "Don't Get Old. Age Better.®” a New Campaign for its Niagen® Brand Featuring Legendary Surfer Kelly Slater
- News
Niagen Bioscience Enters Start-Up Agreement With Mass General Brigham To Plan The Largest And Most Comprehensive Clinical Trial Of Niagen To Date
- Press releaseBusiness Wire
Niagen Bioscience Announces Start-Up Agreement With Mass General Brigham (MGB) Investigators For First-Of-Its-Kind Healthy Aging Clinical Trial
- News
Transcript: Niagen Bioscience Q2 2026 Earnings Conference Call
- News
Niagen Bioscience Highlights Preclinical Research Linking CD38-Driven NAD+ Depletion To Placental Aging; NOTE: Niagen Bioscience Did Not Conduct, Fund, Or Design This Study, And The NR Used Was Not The Company’s Niagen Ingredient
- Press releaseBusiness Wire
Newly Published Preclinical Study Demonstrates CD38 as a Driver of Age-Related NAD+ Decline, Older Mothers Have Lower NAD+ Levels in Placental Tissue, and NAD+ Restoration with Nicotinamide Riboside (NR) Improves Pregnancy Outcomes
- Press releaseBusiness Wire
Niagen Bioscience Engages Veteran Pharmaceutical Executives and Biotechnology Experts to Support Drug Development Program and Strategic Business Growth
- Press releaseBusiness Wire
Niagen Bioscience to Present at Canaccord Genuity’s Well Summit
- Press releaseBusiness Wire
Niagen Bioscience to Present at Longevity Investors Conference
- Press releaseBusiness Wire
Niagen Bioscience to Present at Nasdaq X LD Micro Inaugural SF Summit
- Press releaseBusiness Wire
Niagen Bioscience Expands Tru Niagen® Retail Footprint with GNC and Sam’s Club
- Press releaseBusiness Wire
Niagen Bioscience to Present at the 17th Annual Midwest IDEAS Investor Conference
- News
Niagen Bioscience Announces Availability Of Its Healthy-Aging NAD+ Supplement Tru Niagen On Walmart.com
- Press releaseBusiness Wire
Niagen Bioscience Launches Tru Niagen on Walmart.com, Expanding Access and Diversifying Its E-commerce Marketplace Presence
- News
Niagen Bioscience Q2 EPS $0.01 Misses $0.02 Estimate, Sales $29.785M Miss $30.690M Estimate
- Press releaseBusiness Wire
Niagen Bioscience, Inc. Reports Second Quarter 2026 Financial Results
- Press releaseBusiness Wire
Niagen Bioscience Selects Global Drug Development Pioneer Evotec to Advance Preclinical Development for NB4168
- Press releaseBusiness Wire
Niagen Bioscience Announces a Newly Published Analysis of Past Clinical Studies Demonstrating Niagen® (Patented Nicotinamide Riboside, NR) Supplementation Improved a Muscle-Specific Marker of Biological Aging
- Press releaseBusiness Wire
Niagen Bioscience to Present at Canaccord Genuity’s 46th Annual Growth Conference
- Press releaseBusiness Wire
Niagen Bioscience to Report Second Quarter 2026 Financial Results on Tuesday, August 4, 2026
- Press releaseBusiness Wire
Niagen Bioscience Appoints Abhijit Kale, Ph.D., as Senior Director of Global External Research
- Press releaseBusiness Wire
Niagen Bioscience Receives Exclusive U.S. FDA Rare Pediatric Disease (RPD) Designation and European Medicines Agency Orphan Medicinal Product Designation (OMPD) for NB4168 for the Treatment of Ataxia Telangiectasia (A-T)
- Press releaseBusiness Wire
Niagen Bioscience CEO Rob Fried to Participate in Virtual Fireside Chat to Discuss Pharmaceutical Strategy on July 15, 2026
- Press releaseBusiness Wire
Niagen Bioscience Launches Pharmaceutical Program for Accelerated Aging and Rare Genetic Diseases
- Press releaseBusiness Wire
Niagen Bioscience to Present at the 16th Annual East Coast IDEAS Investor Conference
- Press releaseBusiness Wire
Niagen Bioscience Renames ChromaDex External Research Program to the Niagen Research Program, Strengthening Position as the Global Leader in NAD+ Science
- NewsAvi Kapoor
Snap, Whirlpool, Nerdwallet And Other Big Stocks Moving Lower In Thursday's Pre-Market Session
- NewsEva Mathew
Niagen Bioscience Keeps Full-Year Sales Forecast Intact As Q1 Revenue, Profit Climbs (UPDATED)
- News
Earnings Scheduled For May 6, 2026
- Press releaseBusiness Wire
Niagen Bioscience, Inc. Reports First Quarter 2026 Financial Results
- NewsEva Mathew
Niagen Bioscience Doubles Annual Profit, CEO Signals Acquisition Hunt And GLP-1-Style Expansion— Stock Jumps After-Hours (UPDATED)
- News
Breaking Down Niagen Bioscience: 4 Analysts Share Their Views
- News
12 Health Care Stocks Moving In Thursday's Pre-Market Session
- News
12 Health Care Stocks Moving In Wednesday's After-Market Session
Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.